Support By : Li-lab
| PATHWAY_NAME | REACTOME_ID | KEGG_ID | DRUG_NAME | PUBCHEM_CID | Datasource |
|---|---|---|---|---|---|
| Acute myeloid leukemia | R-HSA-9680350 | map05221 | lidocaine | 3676 | drug-path |
| Melanoma | Q9UHD0-PRO_0000015379 | map05218 | lidocaine | 3676 | drug-path |
| Adipocytokine signaling pathway | R-HSA-168638 | map04920 | lidocaine | 3676 | drug-path |
| Non-small cell lung cancer | R-HSA-5619066 | map05223 | lidocaine | 3676 | drug-path |
| MAPK signaling pathway | R-HSA-9652817 | map04010 | lidocaine | 3676 | drug-path |
| Huntington's disease | R-HSA-1643685 | 0 | lidocaine | 3676 | drug-path |
| RNA polymerase | R-HSA-73864 | map03020 | lidocaine | 3676 | drug-path |
| Olfactory transduction | R-HSA-9751605 | map04740 | ivermectin | 3440 | drug-path |
| Systemic lupus erythematosus | R-HSA-977105 | map05322 | ivermectin | 3440 | drug-path |
| Natural killer cell mediated cytotoxicity | R-HSA-5218921 | map04650 | ivermectin | 3440 | drug-path |
| Neuroactive ligand-receptor interaction | R-HSA-5632681 | map04080 | ivermectin | 3440 | drug-path |
| Hedgehog signaling pathway | R-HSA-5358351 | map04340 | ivermectin | 3440 | drug-path |
| Thyroid cancer | R-HSA-9700206 | map05216 | ivermectin | 3440 | drug-path |
| GnRH signaling pathway | R-HSA-168638 | map04912 | ivermectin | 3440 | drug-path |
| Graft-versus-host disease | R-HSA-1643685 | map05332 | diazoxide | 3019 | drug-path |
| Autoimmune thyroid disease | R-HSA-1643685 | map05320 | diazoxide | 3019 | drug-path |
| Antigen processing and presentation | R-HSA-1236975 | map04612 | diazoxide | 3019 | drug-path |
| Shigellosis | 0 | map05131 | diazoxide | 3019 | drug-path |
| Pathogenic Escherichia coli infection | R-HSA-9609646 | map05130 | diazoxide | 3019 | drug-path |
| Cell adhesion molecules (CAMs) | R-HSA-1031690 | 0 | diazoxide | 3019 | drug-path |